GlassScriptPhysician profile
James R Clark
NPI 1588640650
$13,365.97
in general payments reported to CMS, 2019-2025
44 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,179 · 2020: $1,997 · 2021: $2,833 · 2022: $1,504 · 2023: $1,376 · 2024: $1,316 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,852.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,471.92 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,713.53 | 2019-2025 | Eohilia, Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,559.78 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,492.68 | 2019-2025 | Stelara, Simponi, Remicade |
| Gilead Sciences, INC. | $1,018.84 | 2019-2025 | |
| Pfizer INC. | $586.65 | 2019-2024 | |
| Genzyme Corporation | $258.85 | 2023-2025 | |
| Allergan, INC. | $252.43 | 2019-2020 | |
| Braintree Laboratories, INC. | $222.77 | 2019-2022 | |
| Qol Medical, LLC | $215.39 | 2019-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $198.02 | 2019-2021 | |
| Mauna Kea Technologies, INC. | $188.61 | 2019-2021 | |
| Redhill Biopharma INC. | $156.94 | 2020-2022 | |
| Ucb, INC. | $155.04 | 2019 | |
| Ironwood Pharmaceuticals, INC | $151.19 | 2019-2023 | Linzess |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.